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Skeletal muscle atrophy induced by aging (sarcope-
nia), inactivity, and prolonged fasting states (starva-
tion) is predominantly restricted to glycolytic type II
muscle fibers and typical spares oxidative type I
fibers. However, the mechanisms accounting for
muscle fiber-type specificity of atrophy have re-
mained enigmatic. In the current study, although
the Fyn tyrosine kinase activated the mTORC1
signaling complex, it also induced marked atrophy
of glycolytic fibers with relatively less effect on oxida-
tive muscle fibers. This was due to inhibition of mac-
roautophagy via an mTORC1-independent but
STAT3-dependent reduction in Vps34 protein levels
and decreased Vps34/p150/Beclin1/Atg14 complex
1. Physiologically, in the fed state endogenous Fyn
kinase activity was increased in glycolytic but not
oxidative skeletal muscle. In parallel, Y705-STAT3
phosphorylation increased with decreased Vps34
protein levels. Moreover, fed/starved regulation of
Y705-STAT3 phosphorylation and Vps34 protein
levels was prevented in skeletal muscle of Fyn null
mice. These data demonstrate a Fyn/STAT3/Vps34
pathway that is responsible for fiber-type-specific
regulation of macroautophagy and skeletal muscle
atrophy.INTRODUCTION
Recent studies have demonstrated convergent signals that
control nutrient sensing, cellular energy metabolism, growth,
macromolecular synthesis, and degradation. The AMP-depen-
dent protein kinase (AMPK) represents a central signaling nexus
that responds to changes in intracellular energy status that is
activated upon reduction of cellular energy state (Lage et al.,
2008; Long and Zierath, 2006; Witczak et al., 2008). AMPK is
composed of three subunits: AMP binding to the g subunit thatresults in enhanced a subunit activation loop T172 phosphoryla-
tion and subsequent activation of protein kinase activity (Witczak
et al., 2008). In turn, AMPK downstream targets are quite diverse
and include the phosphorylation of acetyl-CoA carboxylase
to enhance fatty acid oxidation, the phosphorylation of the
tuberous sclerosis complex 2 (TSC2) protein and raptor resulting
in the inhibition of mTORC1 (mammalian target of rapamycin
complex 1)-dependent protein synthesis, and phosphorylation
of ULK1 and FOXO3A to increase macroautophagy (Chiacchiera
and Simone, 2010; Luo et al., 2005; Shackelford and Shaw,
2009; He and Klionsky, 2009; Mizushima, 2010). Macroautoph-
agy is an important catabolic process that mediates degradation
of intracellular components (proteins and organelles) in lyso-
somes and has also been shown to contribute to maintenance
of cellular energetic balance (Singh and Cuervo, 2011). Although
counterintuitive, in several mouse models as well as in human
patients, inhibition of macroautophagy in skeletal muscle has
been linked to muscle atrophy (Grumati et al., 2010; Masiero
et al., 2009; Raben et al., 2008).
In peripheral tissues, AMPK T172 a subunit phosphorylation is
primarily dependent upon the tumor suppressor protein LKB1
(Liver Kinase B1), and inactivating mutations are responsible
for Peutz-Jeghers syndrome, a disorder characterized by
gastrointestinal tract hamartomas and pigmented macules on
the skin and mouth (Alessi et al., 2006; Jansen et al., 2009).
Recently, LKB1 tyrosine phosphorylation through interaction
with the proto-oncogene Fyn has been implicated as an impor-
tant regulatory mechanism for the control of fatty acid oxidation
and insulin sensitivity (Yamada et al., 2010). Fyn is a member of
the Src family of nonreceptor tyrosine kinases and is composed
of two major alternatively spliced isoforms, FynB and FynT, that
differ by the inclusion of exon 7A or exon 7B, respectively (Cooke
and Perlmutter, 1989; Saito et al., 2010). Previous studies have
demonstrated signaling specificities of the two Fyn isoforms, in
that FynT but not FynB expression can efficiently rescue T cell
signaling events in FynT null T cells suggesting cell context-
dependent signaling of the two isoforms (Davidson et al.,
1994). Because previous studies examining the role of Fyn in
insulin action and energy expenditure in vivo relied on Fyn null
mice, it was not possible to distinguish the physiologic contribu-
tions of the two Fyn isoforms. To address this issue, weCell Reports 1, 557–569, May 31, 2012 ª2012 The Authors 557
generated transgenic mice that overexpress either FynB or FynT
selectively in skeletal muscle. Surprisingly, Fyn transgenic mice
display a strong muscle atrophy phenotype with characteristics
similar to sarcopenia and the initial muscle wasting that occurs
during starvation, with selective loss of glycolytic (white) but
not oxidative (red) skeletal muscle fibers. Using Fyn transgenic
and Fyn knockout (KO) mice, we demonstrate that Fyn functions
as part of the nutrient-sensing system to regulate skeletal muscle
fiber-type-specific macroautophagy and muscle degeneration.
RESULTS
Phenotypic Characterization of Fyn-Expressing
Transgenic Mice
Previous studies using Fyn null mice and pharmacological inhibi-
tion of Fyn activity demonstrated that, in muscle and adipose
tissue, Fyn functionally represses fatty acid oxidation and energy
expenditure concomitant with a reduction in AMPK activation
through the inhibition of LKB1 (Bastie et al., 2007; Yamada
et al., 2010). However, because the single fyn gene expresses
two isoforms that cannot be functionally distinguished (either
pharmacologically or by the currently available genetic mouse
model), these data were unable to discriminate between FynT
and FynB activity. To address this issue, we first performed
quantitative PCR (qPCR) to determine the relative tissue-specific
expression of FynT and FynBmRNA (Figure 1A). FynT and FynB
were equally expressed in mouse brain, although FynT was the
predominant transcript expressed in all peripheral tissues exam-
ined, with highest levels found in the spleen, heart, and subcuta-
neous adipose tissue. Intermediate levels of FynT mRNA were
also found in epididymal adipose tissue and skeletal muscle.
To specifically express Fyn isoforms in skeletal but not cardiac
muscle, we used the human skeletal muscle actin (HSA)
promoter to drive FynT or FynB cDNA. As shown in Figure 1B,
we selected transgenic mice that expressed approximately
equal levels of FynT and FynBprotein in both predominant glyco-
lytic skeletal muscle (extensor digitorum longus [EDL]) and
predominantly oxidative skeletal muscle (soleus). Darkened
exposure is shown in Figure 1B (top panel) in order to visualize
the endogenous Fyn protein, and a lightened exposure is shown
in the lower panel. Expression specificity was confirmed
because the levels of FynT (Figure 1C) and FynB (data not
shown) were similar compared to endogenous levels in the brain,
heart, liver, and epididymal adipose tissue.
Visual inspection of the transgenic mice clearly indicated two
predominant abnormalities (Figure 1D). The HSA-FynT mice dis-
played a marked hump behind the neck that was present,
although less pronounced in the HSA-FynB mice, with a marked
reduction in hindquarter mass.
Microcomputed tomography (micro-CT) scans showed that
the protrusion on the back was due to spinal cord malformation
(kyphosis) and confirmed the marked reduction in hindquarter
mass (Figure 1D). Consistent with these observations, age-
matched HSA-FynB transgenic mice had a relatively smaller
(15%) reduction in body mass, whereas the HSA-FynT trans-
genic mice were nearly one-third the weight (10 g lighter) than
control mice (Figure 2A). Quantitative NMR demonstrated that
the relatively reduced weight of the FynT and FynB transgenic558 Cell Reports 1, 557–569, May 31, 2012 ª2012 The Authorsmice was due to a reduction in lean body mass (Figure 2B).
Although there was no significant change in fat mass or water
content in the HSA-FynB mice, there was a small but significant
increase in fat mass with a concomitant decrease in water
content in the HSA-FynT mice. The reduced lean mass was
accompanied by a decrease in skeletal muscle weight with no
change in liver weight (Figures 2C and 2D). Interestingly, soleus
muscle was not significantly affected. The soleus muscle depot
is primarily composed of oxidative (red) muscle fibers, whereas
the other skeletal muscles are either mostly glycolytic white
fibers (i.e., EDL) or a mixture of oxidative and glycolytic muscle
fibers (i.e., gastrocnemius, Gas; tibialis anterior, TA; and quadri-
ceps, Quad).
Previous studies have reported that FynT, but not FynB, can
restore T cell signaling resulting from FynT deficiency and that
FynT has higher kinase activity than FynB (Davidson et al.,
1994). Recent structural analyses have indicated that linker
region of FynB engages the SH3 with higher affinity than the
linker region of FynT. This results in a more autoinhibited and
closed conformation state, thereby markedly reducing the ability
of FynB to interact with and phosphorylate the Src family kinase
substrate Sam68 (Brignatz et al., 2009). To determine the relative
interaction of FynT and FynB with LKB1, epitope-tagged Flag-
LKB1 was coexpressed with epitope-tagged FynT-V5 or equal
amounts of expressed FynB-V5 in cultured 293 cells (Fig-
ure S1A). Immunoprecipitation with the Flag antibody (LKB1) re-
sulted in coimmunoprecipitation of FynT-V5 but substantially
reduced levels of coimmunoprecipitated FynB-V5. Consistent
with reduced substrate kinase activity of FynB versus FynT,
muscle extracts from the HSA-FynB mice displayed an approx-
imate 6-fold increase in Fyn peptide substrate kinase activity
compared to wild-type (WT) mice (Figure S1B). Despite equal
levels of FynT and FynB protein expression (Figure 1B), muscle
extracts from the HSA-FynT mice displayed an approximate
65-fold increase in peptide substrate activity. Thus, the intrinsic
substrate recognition and kinase activities of the FynT and FynB
isoforms likely account for the degree of phenotypic differences.
Histological analysis of the EDLmuscle using hematoxylin and
eosin staining (H&E) revealed a remarkable reduction in muscle
fiber size (10-fold) in the HSA-FynT mice with a relatively
smaller reduction (2- to 3-fold) in muscle fiber size in the soleus
muscle (Figure 2E). Both muscle fibers displayed muscle degen-
eration as seen by nuclear hypertrophy, elongated nuclei, and
myofibril vacuoles (Figure S1C) and was more pronounced in
EDL than soleus muscle. The relative absence of central
migrating nuclei is also consistent with amuscle-wasting pheno-
type. Cytochrome c oxidase and succinate dehydrogenase
staining demonstrated marked increase in mitochondria levels
in EDL muscle of HSA-FynT mice with relatively little change in
soleus muscle (Figure S2). Moreover, there was a marked
increase in nonspecific esterase staining of EDL muscle with
only a small increase in acid phosphatase staining. Alterations
in the staining patterns for these two enzymes have also been
observed in skeletal muscle of other myopathies with compro-
mised autophagic function, such as Danon and X-linked
myopathy (Malicdan et al., 2009). Consistent with the relative
insensitivity of the soleus muscle to FynT expression, there
was a relatively smaller alteration in nonspecific esterase in red
Figure 1. Relative Expression Level of FynT and FynB in Tissues, andGeneration of Skeletal Muscle-Specific FynB and FynT TransgenicMice
(A) mRNA expression levels of FynB (open bars) and FynT (solid bars) relative to cyclophilin A in brain, spleen, heart, epididymal (WAT) and subcutaneous (SubQ)
adipose tissues, gastrocnemius (Gas), and soleus muscle are shown.
(B) Fyn protein expression in soleus and EDL skeletal muscles of WT, HSA-FynT, and HSA-FynB transgenic (Tg) mice is illustrated in the upper panels. Tubulin
was used as internal loading control. A lighter exposure of the Fyn immunoblot (top panel) is shown below the tubulin immunoblot.
(C) Fyn protein levels in the brain, heart, liver, and epididymal adipose tissue of WT and HSA-FynT transgenic (Tg) mice are shown. Actin was used as internal
loading control.
(D) Physical characteristics (left panels) and micro-CT pictures (right panels) for WT, HSA-FynB, and FynT transgenic mice.
See also Figure S1.oxidative soleus muscle fibers and a similarly small increase
of acid phosphatase compared to the EDL muscle fibers
(Figure S2).Ultrastructural disorganizationof skeletalmuscle fibers inHSA-
FynT transgenicmicewas also observed by electronmicroscopy
in both mixed (tibialis anterior) fiber muscles (Figure 3A) andCell Reports 1, 557–569, May 31, 2012 ª2012 The Authors 559
Figure 2. Skeletal Muscle Atrophic Characteristics of HSA-FynT and HSA-FynB Transgenic Mice
(A) Total body weight of HSA-FynB (FynB) and HSA-FynT (FynT) mice and their respective control littermates (WT) is shown. *p < 0.005 versus WT.
(B) Quantification of fat and lean mass measured by NMR in HSA-FynB (left panel) and HSA-FynT (right panel) mice versus their respective control littermates.
*p < 0.05, **p < 0.01 versus WT, respectively.
(C) Selective muscle sizes from WT, HSA-FynB, and HSA-FynT mice. Gas, gastrocnemius; TA, tibialis anterior; Quad, quadriceps.
(D) Total tissue weight (liver, gastrocnemius, quadriceps, tibialis anterior, EDL, and soleus muscles) of WT littermates, HSA-FynB and HSA-FynT transgenic mice.
Data are expressed as mean ± SEM. *p < 0.005 versus WT.
(E) H&E of EDL and soleus muscle from WT and HSA-FynT mice.
See also Figure S2.glycolytic EDLmuscle (Figure S3A)with lesser effects in oxidative
soleus muscle fibers (Figure S3B). The HSA-FynT mice also dis-
played intrafiber Z-band breakswith expanded and disorganized
mitochondria and sarcoplasmic reticulum structures. Further560 Cell Reports 1, 557–569, May 31, 2012 ª2012 The Authorsevidence for glycolytic muscle wasting is based upon the greater
extent of fibrosis, trichrome staining for collagen deposition, and
expression of the proinflammatory/fibrosis cytokine, TGF-b1, in
EDL versus soleus muscle (Figure S4).
Figure 3. HSA-Fyn Mice Display Defective Macro-
autophagy
(A) Transmission electron microscopy images of tibialis
anterior muscle from WT (left) and HSA-FynT (right) mice.
Large arrows indicate expanded mitochondria, small
arrows indicate Z line disruption, and arrowheads indicate
expanded sarcoplasmic reticulum.
(B) LC3-I and LC3-II protein levels in gastrocnemius
muscle of WT and HSA-FynT (lower) compared to WT and
HSA-FynB mice (upper) from two independent animals
each.
(C) Tibialis anterior muscle of WT, HSA-FynB, and HSA-
FynT mice was transfected with GFP-LC3 as described in
Experimental Procedures. The free-cleaved GFP (lower
band) generated by autophagy from the GFP-LC3 fusion
protein (upper bands) was detected by immunoblotting
with a GFP mouse monoclonal antibody. Immunoblotting
for the GAPDH protein (C and D) was used as a loading
control.
(D) Gastrocnemius muscles of WT, HSA-FynT, and HSA-
FynB mice were immunoblotted with p62, phosphoY705-
STAT3, total STAT3, and vps34 antibodies from two
independent animals. GAPDH was used as internal
loading control.
See also Figure S3.FynT Enhances Skeletal Muscle mTORC1 Signaling
and Inhibits Macroautophagy
Recent studies have demonstrated that defective mTORC1
signaling results in muscle atrophy of glycolytic muscle fibers
with a lesser effect on oxidative muscle fibers (Bentzinger et al.,
2008; Risson et al., 2009). In contrast, AMPK-deficient mice
have muscle hypertrophy due to enhanced mTORC1 activity
(Lantier et al., 2010; Mounier et al., 2009). Because Fyn null
mice have increased skeletal muscle AMPK activity, and AMPK
is an established inhibitor ofmTORC1-dependent signaling (Kim-
ball, 2006; Shackelford and Shaw, 2009), we anticipated that
increased Fyn expression would inhibit AMPK and thereby result
in mTORC1 activation. In turn, increased Fyn expression would
be expected to drive muscle hypertrophy, opposite to the
observed muscle atrophy phenotype. Therefore, to determine if
increased Fyn expression did in fact result inmTORC1activation,
we examined AMPK and mTORC1 target site phosphorylation
(Figure S5A). Consistent with previous studies in Fyn null mice
that show increased AMPK activation, HSA-FynT transgenicCell Reports 1mice displayed reduced skeletal muscle
phosphorylation of the T172 AMPK a subunit
activation site. In parallel there was a marked
reduction in AMPK-specific raptor inhibitory
site phosphorylation (S792) and increased
mTORC1-specific S6 kinase activation site
phosphorylation (S389). In addition, FynT
expression resulted in enhanced LKB1 tyrosine
phosphorylation, consistentwith LKB1 inhibition
resulting in reduced AMPK activation (Yamada
et al., 2010). Functional activation of AMPK in
HSA-FynTmicewas further confirmed by down-
regulation of PGC1a and induction of ACC1a
expression (Figures S5C and S5D).mTORC1 activation would be expected to increase muscle
mass, yet we observed an opposite phenotype, suggesting the
presence of another overriding mechanism. In this regard, defi-
ciency of skeletal muscle macroautophagy (acid a-glucosidase
as seen in Pompe KO mice) results in marked skeletal muscle
atrophy in glycolytic fibers but with less of an effect in oxidative
fibers (Raben et al., 2008). In addition, Pompe mice display
a similar spinal cord deformation. Furthermore, inhibition of
macroautophagy initiation by conditional ATG7-specific KO in
skeletal muscle resulted in similar morphological features of
muscle wasting (Masiero et al., 2009). Because our morpholog-
ical and histological analyses are also consistent with a defect in
lysosome function (Figure S2), we speculated that FynT expres-
sion might also inhibit skeletal muscle macroautophagy.
To assess this possibility, we first examined the levels and
degradation kinetics of LC3-II, an integral component of the au-
tophagosome membrane that is widely utilized as a marker of
this compartment (Kabeya et al., 2000). Levels of LC3-I, a primed
form of the protein precursor of LC3-II, were substantially, 557–569, May 31, 2012 ª2012 The Authors 561
Figure 4. Autophagy Is Differentially Regulated in Fast-Twitch Glycolytic Type II Fibers and Slow-Twitch Oxidative Type I Fibers of HSA-FynT
Mice
(A) Representative p62 immunofluorescence (IF) and DAPI staining (blue) images from EDL and soleus muscle of WT and HSA-FynT mice.
(B) Representative transmission electron microscopic images of tibialis anterior muscles fromWT and HSA-FynT (FynT) mice. Examples of autophagic vacuoles
(denoted by arrows in the low-magnification field) are shown at higher magnification in the insets.
(C) Quantification of autophagic vacuoles (AV) by transmission electron microscopy in tibialis anterior (TA), EDL, and soleus muscles from WT (open bars) and
HSA-FynT (filled bars) mice. The average number of autophagic vacuoles per field was quantified by morphological analyses of at least 15 electron microscopy
images from 3 independent mice.
(D) Beclin1 and Beclin1 complex-related protein (Vps34, Atg14, UVRAG, Bcl2, and phospho-Bcl-2) expression levels in EDL and soleus muscles of WT and
HSA-FynT mice are shown. GAPDH was used as internal loading control. These are representative immunoblots independently performed three times.
(E) mRNA expression levels (upper) and protein levels (lower) of Vps34 relative to Hrpt1 or GAPDH in EDL and soleusmuscles ofWT andHSA-FynTmice. *p < 0.05
versus WT (top panel) and *p < 0.01 versus WT (bottom panel).
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increased, and steady-state levels of LC3-II were decreased in
the gastrocnemius muscle of both HSA-FynT and HSA-FynB
mice (Figure 3B). Although these findings are supportive of
reduced autophagosomes formation, lower autophagosome
content may also result from accelerate degradation of these
vesicular compartments in lysosomes. To assess autophagic
vacuole clearance, we transfected the tibialis anterior muscle
in vivo with a GFP-LC3 reporter, which when delivered into lyso-
somes is proteolytically cleaved to free GFP, with the LC3 insert
rapidly degraded in this compartment. Lysosomal cleavage of
GFP-LC3 in skeletal muscle was substantially reduced in the
HSA-FynT mice with an intermediate amount of cleavage in the
HSA-FynB mice (Figure 3C) as compared to WT mice. These
data suggest that the lower levels of endogenous LC3-II
observed in Fyn transgenic mice result from decreased autopha-
gosome formation rather than from accelerated degradation.
Similarly, the well-characterized macroautophagy substrate
protein SQSTM1/p62 (Masiero et al., 2009; Mizushima et al.,
2010) was substantially increased in gastrocnemius (mixed
muscle) of HSA-FynT mice with moderate increase in HSA-
FynB mice compared to WT mice (Figure 3D, top panel). We
also confirmed the increase in SQSTM1/p62 protein levels and
its presence in aggregate-like structures in the gastrocnemius
muscle by immunofluorescence (data not shown). Macroau-
tophagy inhibition was also accompanied by accumulation
of ubiquitinated proteins that has also been reported inmacroau-
tophagy-deficient skeletal muscle (Klionsky et al., 2008)
(Figure S5B).
A relative selective perturbation of glycolytic muscle macroau-
tophagy was observed based upon SQSTM1/p62 immunofluo-
rescence and the quantification of autophagic vacuoles in the
EDL and soleus muscle. SQSTM1/p62 immunofluorescence
intensity was increased to a greater extent in the EDL compared
to soleus muscles in the HSA-FynT mice (Figure 4A). Transmis-
sion electron microscopy demonstrated the presence of auto-
phagic vacuolar structures as vesicular compartments with
double- or single-limiting membrane-containing heterogeneous
cytosolic material (Figure 4B). Morphometric quantification of
these autophagic vacuolar structures demonstrated a decrease
in tibialis anterior and EDL muscles with an increase in soleus
muscle of the HSA-FynTmice compared toWTmice (Figure 4C).
The lower content of autophagic vacuoles in glycolytic skeletal
muscles supports the inhibitory effect of Fyn on autophagosome
formation inferred from the cell biological analysis.
Activation of the FOXO family of transcription factors, espe-
cially FOXO3a, has been reported to induce muscle mass loss
through the induction of atrophy-related muscle-specific E3
ubiquitin ligase genes (MuRF1 and atrogin-1) and by stimulation
of autophagy by proapoptotic Bcl family members, Bnip3 and
Bnip3L (Mammucari et al., 2007; Sandri et al., 2004). Although
AMPK has been reported to be an upstream activator of FOXO3a
(Chiacchiera and Simone, 2010; Greer et al., 2007), AMPK
activity was decreased in the HSA-FynT mice (Figure S5A), sug-(F) Vps34 presence in Beclin1 complex 1 (containing Atg14) and Beclin1 comple
determined by immunoprecipitation (IP) using either an Atg14 or UVRAG anti
antibodies. These are representative immunoblots independently performed thre
See also Figure S4.gesting a FOXO3a-independent atrophymechanism. Consistent
with this prediction, qPCR demonstrated decreased expression
of MuRF1, atrogin-1, as well as the proapoptotic BH3 domain
proteins Bnip3 and Bnip3L in the EDL muscle of the HSA-FynT
mice with no change in soleus muscle (Figure S6). Moreover,
dystrophin expression was increased in the EDL muscle of
HSA-FynT mice and was unchanged in soleus muscle. In
contrast, lysosomal proteinase, Cathepsin L, expression is upre-
gulated in various skeletal muscle atrophy models (Bechet et al.,
2005) andwas elevated in both the EDL and soleusmuscle of the
HSA-FynT mice. The relative sensitivity of EDL versus soleus
muscle to Fyn expression likely reflects an intrinsic difference
in these muscle fibers because FynT expression was similar in
both depots (Figure S7B).
FynT Enhances STAT3 Tyrosine Phosphorylation and
Alters Vps34 Protein Levels and the Assembly State of
the Vps34/p150/Beclin1/Atg14 Complex 1
It is well established that mTORC1activation results in inhibition
of macroautophagy, and in mammalian cells appears to result
from the phosphorylation and inactivation of the ULK1/Atg13/
FIP200 complex (He andKlionsky, 2009;Mizushima, 2010). Simi-
larly, recent studies have reported that AMPK directly phosphor-
ylates ULK1 to promote macroautophagy (Egan et al., 2011; Kim
et al., 2011). However, activation of mTORC1 through the inhibi-
tion of AMPK is known to induce muscle hypertrophy (Lantier
et al., 2010; Mounier et al., 2009). Despite mTORC1 activation
and reduced AMPK in the HSA-FynT mice, we observed a
muscle-wasting phenotype. Because the relative contribution
of mTORC1 in the regulation of macroautophagy in skeletal
muscle remains poorly defined (Sandri, 2010; Zhao et al., 2007),
we speculated that the presence of an mTORC1-independent
mechanism is responsible for the control of macroautophagy.
To address this issue, we examined protein levels of the class
3 phosphatidylinositol kinase (PIK3C3 gene or Vps34 protein)
complex 1 and complex 2 that regulate macroautophagy and
endosome trafficking, respectively, independent of mTORC1
function (Funderburk et al., 2010; He and Klionsky, 2009).
Vps34 protein levels were decreased in EDL muscle of HSA-
FynT mice, but not soleus muscle, a finding that is consistent
with the inhibition of macroautophagy in glycolytic muscle (Fig-
ure 4D). Although there was no significant change in protein
levels of Atg14 and UVRAG, there was an increase in Beclin1
protein with a small increase in Bcl-2 protein, but no change in
Bcl-2 phosphorylation. The large decrease in the EDL muscle
was predominantly due to downregulation of Vps34 protein
with only a small decrease in Vps34 mRNA. Similarly, the smaller
reduction in Vps34 protein in soleus muscle occurred without
any significant change in Vps34 mRNA (Figure 4E).
The relative changes in the individual Beclin1, Vps34, Bcl-2,
Atg14, and UVRAG components do not necessarily indicate
the status of the required macroautophagy complex 1, Vps34/
p150/Beclin1/Atg14 (Funderburk et al., 2010; Itakura andx 2 (containing UVRAG) in quadriceps muscle of WT and HSA-FynT mice was
body followed by immunoblotting with Vps34, Beclin1, Atg14, and UVRAG
e times.
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Figure 5. STAT3 Is Tyrosine Phosphorylated in EDL but Not Soleus
Muscle of HSA-FynT Mice, and the Dominant-Negative Form of
STAT3 Rescues Autophagy Deficiency in HSA-FynT Mice
(A) EDL and soleus muscles isolated from WT and HSA-FynT mice were
immunoblotted with phosphoY705-STAT3 and total STAT3 antibodies from
two independent animals.
(B) Tibialis anterior muscles of WT mice were transfected with either an empty
vector () or the vector containing the dominant-interfering (+) STAT3 mutant
(Flag-STAT3-Y705F), and autophagic flow was determined as described in
Experimental Procedures.
(C) Beclin1 complex-related protein expression levels in the tibialis anterior
muscles ofWTmice transfected with empty vector () or Flag-STAT3-Y705F (+).
(D) Tibialis anterior muscles of HSA-FynT mice were transfected with empty
vector () or the vector containing the dominant-interfering (+) STAT3 mutant
(Flag-STAT3-Y705F) followed by determination of autophagic flow.
(E) Beclin1 complex-related protein expression levels in the tibialis anterior
muscles of HSA-FynT mice transfected with an empty vector () or Flag-
STAT3-Y705F (+). These are representative immunoblots independently
performed four times for (A) and three times for (B)–(E).
(F) Tibialis anterior muscles of HSA-FynT mice were transfected with empty
vector () or the vector containing the Vps34 (Myc-Vps34) followed by
determination of autophagic flow.
See also Figure S5.
564 Cell Reports 1, 557–569, May 31, 2012 ª2012 The AuthorsMizushima, 2009). We therefore examined the assembly state
of complex 1 by Atg14 coimmunoprecipitation (Figure 4F). As
previously shown for EDL muscle, mixed fiber quadriceps
muscle from HSA-FynT mice had reduced protein levels of
Vps34 but increased levels of Beclin1. Immunoprecipitation of
Atg14 demonstrated near-complete loss of Vps34 from
complex 1 in HSA-FynT mice, with a concomitant increase in
Beclin1 coimmunoprecipitated with Atg14. As a control, Vps34/
Beclin1/UVRAG complex 2 that is involved in Rab5- and Rab7-
positive endosome sorting was essentially unaffected (Backer,
2008; Funderburk et al., 2010). Together, thesedata demonstrate
that FynT expression in skeletal muscle results in the loss of
Vps34 from the Vps34/p150/Beclin1/Atg14 complex 1 that is
required for macroautophagy that functions independent of
mTORC1 regulation (Funderburk et al., 2010; He and Klionsky,
2009).
Blockade of STAT3 Signaling Reverses FynT Inhibition
of Macroautophagy
To identify potential Fyn substrate targets, we next performed
a phosphotyrosine proteome screen comparing skeletal muscle
from Fyn null mice with HSA-FynT transgenic mice. Tyrosine-
phosphorylated STAT3 was significantly increased in the HSA-
FynT skeletal muscle compared to Fyn null mice. Increased
Y705-STAT3 phosphorylation was confirmed by phosphotyro-
sine immunoblotting of HSA-FynT andHSA-FynBgastrocnemius
muscle (Figure 3D). Consistent with weaker penetrance of HSA-
FynB compared to HSA-FynT mice in terms of kyphosis, muscle
mass, andmacroautophagymarkers, Y705-STAT3phosphoryla-
tion and the downregulation of Vps34 proteins were more robust
in the HSA-FynT compared to HSA-FynB mice.
As observed in gastrocnemius muscle, EDL muscle from
HSA-FynT mice displayed robust Y705F-STAT3 tyrosine phos-
phorylation but with only a small increase in STAT3 tyrosine
phosphorylation in soleus muscle (Figure 5A). Expression of
the dominant-interfering STAT3 mutant (STAT3-Y705F) mark-
edly increased autophagic flow in WT tibialis anterior muscle
(Figure 5B). In parallel there was also a marked induction of
Vps34 protein expression (Figure 5C). Surprisingly, there was
also increased expression of Beclin1 and Atg14. The fact that
Beclin1 was also increased by FynT expression and by expres-
sion of the dominant-interfering STAT3 mutant suggests that
the effect on Beclin1 is indirect. Nevertheless, STAT3-Y705F
expression in tibialis anterior muscle of HSA-FynT mice reacti-
vated autophagic flow and increased Vps34 protein expression
(Figures 5D and 5E). In this case the ability of STAT3-Y705F to
increase Beclin1 and Atg14 protein levels was somewhat
reduced compared to WT muscle. Moreover, Vps34 expression
also restored autophagic flow to HSA-FynT tibialis anterior
muscle (Figure 5F) Taken together, these data support a model
in which STAT3 functions upstream of Vps34.
Skeletal Muscle Fiber-type-Specific Regulation of
Endogenous STAT3 Tyrosine Phosphorylation and
Vps34 Expression by Food Restriction/Refeeding
The data presented above reflect the effect of Fyn overexpres-
sion onmuscle atrophy andmacroautophagy but do not address
the role of these events in normal physiological conditions. To
Figure 6. Beclin1 and Beclin1 Complex-Related Proteins Are
Differentially Regulated in the EDL and Soleus Muscles of WT
Animals in the Refed State
(A) WT mice were food restricted for 30 hr (starved) and then allowed free
access to food for 5 hr (refed). The EDL and soleus muscles were isolated and
immunoblotted for LC3 in two independent animals. These are representative
immunoblots independently performed three times.
(B) mRNA expression levels (left) and protein levels (right) of Vps34 relative
to Hrpt1 or GAPDH in EDL and soleus muscles of starved and refed WT mice.
*p < 0.05 versus starved state (left panel) and * p< 0.01 versus starved state
(bottom panel).
(C) The EDL and soleusmuscles from starved and refedWTmice (lysates) were
immunoprecipitated (IP) with an ATG14 antibody and immunoblotted for
Vps34, Beclin1, and Atg14. These are representative immunoblots indepen-
dently performed three times.
See also Figure S6.address this issue, we examined skeletal muscle fiber-type-
specific signaling under prolonged food restriction conditions
that induce, and following refeeding that suppresses, skeletal
musclemacroautophagy inWTmice (Masiero et al., 2009; Ogata
et al., 2010). As expected, the upstreammTORC1 activator, Akt,
displayed enhanced activation site phosphorylation (T308 andS473) in the refed state compared to the starved state. Similarly,
mTORC1 activation paralleled the increased activation of Akt as
detected by activation site phosphorylation of the mTORC1
downstream target S6 kinase. In contrast, a subunit activation
site threonine (T172) of AMPK was increased in starved state
and reduced in the refed state. Importantly, the phosphorylation
of AMPK, Akt, and the mTORC1-specific substrate S6K1 phos-
phorylation site were essentially identical between the oxidative
soleus and glycolytic EDL muscle (Figures S7 and S7A).
Although total LC3 protein levels were greater in soleus
compared to EDL muscle, in the refed state only LC3-I was
detectable in EDL muscle, whereas both LC3-I and a smaller
amount of LC3-II were presented in the soleus muscle (Fig-
ure 6A). In the starved state, LC3-II levels increased with a
concomitant reduction of LC3-I in EDL muscle, whereas there
was a relatively smaller increase in LC3-II in soleus muscle
following starvation. Moreover, 30 hr of food restriction
increased Vps34 protein levels in EDL muscle with no significant
change in Beclin1, Atg14, UVRAG, or Bcl-xl protein levels,
although there was also a concomitant increase in Bcl-2 protein
levels. Consistent with the soleus muscle being refractory to
changes in STAT3 Y705 phosphorylation, prolonged food
restriction had no statistically significant effect on Vps34, Be-
clin1, Atg14, or UVRAG protein levels in soleus muscle, although
there was again a small increase in Bcl2 and a nonsignificant
increase in Bcl-xl protein levels. Because macroautophagy is in-
hibited in the refed state and both Bcl-2 and Bcl-xl can suppress
macroautophagy, the decrease in these proteins is not consis-
tent with a block of macroautophagy in the refed state. As
observed in HSA-FynT mice, the reduction in Vps34 levels in
EDL muscle of fed mice was due to a selective decrease in
Vps34 protein levels and was accompanied by only a small
decrease in Vps34 mRNA (Figure 6B).
We next examined the assembly state of the Vps34/p150/
Beclin1/Atg14 in EDL and soleus muscle in starved and refed
WT mice (Figure 6C). Immunoprecipitation of Atg14 from EDL
muscle demonstrated reduced coimmunoprecipitation of Vps34
in the refed mice. In contrast the amounts of Beclin1 and Vps34
coimmunoprecipitated with Atg14 were essentially unchanged
in starved and refed soleus muscle. These data demonstrate
that in WT mice the Vps34/Beclin1/Atg14 complex 1 is regulated
by starvation/refeeding in a skeletalmuscle fiber-specificmanner
analogous to that of transgenic overexpression of Fyn.
Regulation of STAT3 Tyrosine Phosphorylation
and Vps34 Protein Levels by Restriction/Refeeding
Is Fyn Dependent
Although food restriction for 30 hr followed by refeeding for 5 hr
had no significant effect on endogenous Fyn protein expression
levels (Figure 7A), Fyn protein kinase activity was increased
approximately 2-fold in starved compared to refed glycolytic
EDL muscle (Figure 7B). In contrast there was little effect on
Fyn kinase activity in the oxidative soleus muscle. In parallel,
EDL muscle displayed increased Y705 phosphorylation of
STAT3 following refeeding, whereas there was no significant
change in soleus muscle (Figure 7C).
To demonstrate that endogenous Fyn functions upstream of
endogenous STAT3 and Vps34 genetically, we examined theCell Reports 1, 557–569, May 31, 2012 ª2012 The Authors 565
Figure 7. Autophagy Is Differentially Regulated in the EDL and
Soleus Muscles of WT Mice in the Starved and Refed State
(A) EDL and soleus muscles from starved and refed WT mice were immuno-
blotted (IB) for Fyn protein levels in two independent animals.
(B) Fyn protein kinase activity in the EDL and soleus muscles of starved and
refedWTmice was determined as described in Experimental Procedures from
five independent mice. *p < 0.05 versus starved.
(C) EDL (upper) and soleus muscles (lower) from starved and refed WT mice
were immunoblotted for pY705-STAT3 and total STAT3 protein levels in two
independent animals.
(D) Quadriceps muscles of Fyn KO and WT mice were immunoblotted with
Vps34, phosphoY705-STAT3, and total STAT3 from two independent animals.
GAPDH was used as internal loading control.
(E) LC3-I, LC3-II, and p62 protein levels in quadriceps muscle of Fyn KO and
WT mice from two independent animals each. These are representative
immunoblots independently performed three times in (A) and (C)–(E).
See also Figure S7.effect of starvation/refeeding in Fyn null mice. As previously
observed, Vps34 protein levels were decreased and Y705-
STAT3 phosphorylation was increased in quadriceps muscle in
refed WT mice compared to starved mice (Figure 7D). In
contrast, Vps34 protein levels remained unchanged in starved
and refed Fyn null mice. In parallel there was no detectable
increase of Y705-STAT3 phosphorylation in refed Fyn null
mice. LC3-II levels were also increased in starved Fyn null
mice concomitant with decreased p62 levels compared to
WT mice (Figure 7E).566 Cell Reports 1, 557–569, May 31, 2012 ª2012 The AuthorsDISCUSSION
Muscle mass is maintained over time by two opposing
processes, protein synthesis and degradation, that serve to
increase and decrease muscle fiber size, respectively. These
processes are regulated by a variety of intracellular and extracel-
lular cues, including nutritional status. During states of nutritional
deprivation (i.e., prolonged fasting), muscle wasting occurs
through degradation of intracellular macromolecular compo-
nents via the proteasome and lysosome-degradation systems,
with the latter also used to generate substrates for energy
production. In contrast, during nutritional excess the available
substrates are used for macromolecular synthesis to increase
muscle mass. The dynamic balance between these opposing
processes is critical in maintaining appropriate muscle mass.
A variety of studies have established that the major pathway
regulating muscle protein synthesis includes activation of the
mTORC1 protein kinase complex, composed of the serine/thre-
onine kinase mTOR plus the regulatory-associated proteins
Raptor, LST8/GbL, PRAS40, and Deptor (Kazi et al., 2011; Lee
et al., 2007). The mTORC1 complex activates the initiation of
protein synthesis through phosphorylation and activation of the
S6 kinase and phosphorylation and inhibition of 4E-BP1 that
suppresses 50 mRNA-capping protein eIF4E (Lee et al., 2007).
mTORC1 itself is subject to a complex set of upstream regulators
that integrate signaling from hormones, nutrients, amino acids,
lipids, and redox state (Howell and Manning, 2011). Under
normal fed nutritional states, growth factors induce Akt activa-
tion that both inhibits TSC2 GAP activity and directly stimulates
mTORC1 protein kinase activity. In addition, amino acids,
particularly leucine, also activate mTORC1 through an as yet
undefined mechanism that involves the Rag family of small
GTP binding proteins and lysosomal targeting (Sancak et al.,
2010). In contrast, during fasting/starvation or contraction, the
decrease in muscle energy (ATP) and increase in AMP result in
the activation of the AMPK that phosphorylates Raptor and
blocks mTORC1 substrate recognition and activates the TSC2
GAP activity thereby suppressing mTORC1 function.
AMPK and mTORC1 also integrate with the macroautophagy
system through the ULK1/Atg13/FIP200 complex (He and Klion-
sky, 2009; Mizushima, 2010). AMPK induces macroautophagy
by ULK1 activation site phosphorylation site, whereas mTORC1
phosphorylation of ULK1 inhibits its kinase activity and blocks
phagophore formation (Egan et al., 2011; He and Klionsky,
2009; Kim et al., 2011). This integrative response between
mTORC1 and macroautophagy provides a driving mechanism
for the dynamic balance of protein synthesis and degradation
in the maintenance of muscle mass in the fed and fasting state.
This is consistent with genetic blockade of mTORC1 function re-
sulting in muscle wasting, and in opposition, inhibition of AMPK
that activates mTORC1 results in muscle hypertrophy (Bent-
zinger et al., 2008; Lantier et al., 2010). Surprisingly, however,
genetic blockade of macroautophagy as in Pompe mice results
in muscle wasting in a fiber type-specific manner (Raben et al.,
2008). Similarly, muscle wasting in aging (sarcopenia) also
occurs in a fiber type-specific manner, primarily affecting
fast-twitch glycolytic type II fibers with sparing of slow-twitch
oxidative type I fibers (Bassel-Duby and Olson, 2006).
Interestingly, Fyn transgenic and Pompe mice both display
spinal cord curvature (kyphosis), whereas there is no reported
indication for this phenotype in ATG7 skeletal muscle-deficient
mice (Masiero et al., 2009). One possible explanation is that
both the Fyn transgenic and Pompe mice have selective inhibi-
tion of glycolytic muscle macroautophagy that has little effect
in oxidative muscle, whereas deletion of ATG7 results in macro-
autophagy inhibition in both muscle fiber types.
In any case the data presented in this study provide evidence
for an alternative AMPK/mTORC1-independent pathway that
may account for the muscle fiber-type specificity of macroau-
tophagy regulation and muscle wasting. The nonreceptor
tyrosine kinase Fyn has previously been shown to function as
an upstream regulator of AMPK, fatty acid metabolism, and
energy expenditure pathways that are integral to muscle mass
maintenance and macroautophagy (Hardie, 2011). Because
Fyn inhibits AMPK activation and increases mTORC1 activity,
we expected an induction of muscle hypertrophy analogous to
that seen in AMPK KO mice (Lantier et al., 2010). Although over-
expression of Fyn does, in fact, activate mTORC1 concomitant
with inhibition of AMPK, these mice display marked muscle
wasting. Starvation-induced inhibition and refeeding-induced
activation of mTORC1were essentially identical in both oxidative
and glycolytic muscles. Thus, the changes in mTORC1 activity
per se do not account for the differing sensitivity of the soleus
and EDL muscles to macroautophagy regulation. However,
Fyn kinase activity was specifically activated in glycolytic muscle
in the fed state that directly correlated with STAT3 tyrosine
phosphorylation and reduction in Vps34 protein expression.
Reduction in Vps34 protein primarily resulted in decreased
content of the Vps34/Beclin1 complex 1 that is recruited to the
site of autophagosome formation.
The Vps34/Beclin1 complex generates PI3P production
necessary for phagophore elongation at the Atg7-dependent
conjugation steps (He and Klionsky, 2009). In addition, PI3P
plays critical roles in membrane transport, trafficking, and
membrane fusion events (Backer, 2008; Noda et al., 2010).
Consistent with an essential role of Vps34, overexpression of
Fyn reduced Vps34 protein levels and the amount of the
Vps34/Beclin1 complex 1. The most immediate consequence
of the reduced levels of complex 1 in the transgenic mice is a
decrease in macroautophagy that appears to occur at multiple
steps (including the conversion of LC3-I to LC3-II and reduced
autophagic flow with decreased autophagic vacuoles). Impor-
tantly, in the refed state in which macroautophagy is inhibited,
endogenous Fyn tyrosine kinase activity was unaffected in
oxidative muscle but increased in glycolytic muscle. In contrast
in the starved state where macroautophagy is activated, Fyn
activity was decreased in glycolytic muscle and again un-
changed in soleus muscle. The relative changes in Fyn kinase
activity directly correlated with STAT3 tyrosine phosphorylation
and Vps34 protein levels. Furthermore, the Fyn-dependent
decrease in Vps34 protein levels and inhibition of macroautoph-
agy were reversed by expression of a dominant-interfering
STAT3 mutant and by overexpression of Vps34.
Importantly, wewere able to genetically place Fyn upstream of
STAT3 and Vps34 because the Fyn null mice failed to induce
STAT3 tyrosine phosphorylation or to decrease Vps34 proteinlevels in the fed state. Taken together, these data support the
presence of a Fyn/STAT3/Vps34 pathway that selectively regu-
lates glycolytic muscle wasting independent of the classical
mTORC1 pathway. Future studies are now needed to determine
the upstream nutrient/hormone signals that regulate Fyn kinase
activity in a muscle fiber-type-specific manner and the specific
signaling mechanisms controlling Vps34 protein synthesis and/
or degradation.
EXPERIMENTAL PROCEDURES
Transgenic Mice
Mice overexpressing murine FynB and FynT cDNA were generated using the
HSA promoter with the SV40 polyadenylation and intron sequences (Khan
et al., 2001) as detailed in Extended Experimental Procedures. HSA-FynB,
HSA-FynT, and control littermates were housed in a facility equipped with
a 12 hr light/dark cycle. Animals were fed ad libitum a standard chow diet
(Research Diets, New Brunswick, NJ, USA) containing 67% (Kcal) carbohy-
drates, 19% protein, and 4% fat. All studies were approved by and performed
in compliance with the guidelines of the Albert Einstein College of Medicine
Institutional Animal Care and Use Committee (IACUC).
Antibodies and Reagents
All antibodies and reagents were obtained from commercial sources as
detailed in Extended Experimental Procedures.
qPCR Analysis
mRNA expression levels were determined by SYBR green (QIAGEN, Valencia,
CA,USA)orbyTaqMan (AppliedBiosystems,Branchburg,NJ,USA)quantitative
reverse-transcription PCR as detailed in Extended Experimental Procedures.
MRI and Micro-CT Scanning
Fat and lean mass was determined using the EchoMRI-3-in-1 System from
Echo Medical Systems (Houston). Briefly, 10-week-old animals were placed
in a clear-plastic holder without anesthesia or sedation and inserted into the
EchoMRI-3-in-1 System. Micro-CT scans were performed on 16-week-old
mice using the Aloka LaTheta laboratory CT scan machine (Aloka, System
Engineering, Tokyo).
Histology and Electron Microscopy
Muscle samples for histology were stained with H&E, cytochrome c oxidase,
succinate dehydrogenase, nonspecific esterase, acid phosphatase, and Go¨-
mo¨ri trichrome as described by Malicdan et al. (2009) as detailed in Extended
Experimental Procedures. Muscle samples for electron microscopy were
prepared and analyzed as previously described by Koga et al. (2010) as
detailed in Extended Experimental Procedures.
Western Blotting and Immunoprecipitation
Immunoblotting and immunoprecipitation of various skeletal muscle proteins
were performed using standard procedures as detailed in Extended Experi-
mental Procedures.
Fyn Kinase Activity
Fyn tyrosine kinase activity was determined with a Universal Tyrosine kinase
activity assay kit (Takara Bio, Shiga, Japan) according to the manufacturer’s
instructions as detailed in Extended Experimental Procedures.
Skeletal Muscle Transfection In Vivo
The tibialis anterior muscle was transfected with cDNA vectors by electropo-
ration as detailed in Extended Experimental Procedures.
Autophagic Flow
Tibialis anterior muscles of mice fasted for 21 hr were cut into pieces and incu-
bated into oxygenated DMEM supplemented with 10% FBS either with or
without 40 mM NH4Cl, 100 mM leupeptin for 1 hr.Cell Reports 1, 557–569, May 31, 2012 ª2012 The Authors 567
Statistics
Results are expressed as mean ± SEM. Differences between animals and/or
treatments were tested for statistical significance using Student’s unpaired
t test.
SUPPLEMENTAL INFORMATION
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